Clinical Research

Pacific Pulmonary Medical Group actively pursues promising research, offering patients the opportunity to be among the first to benefit from advances in medicine. Everyday research uncovers new information about diseases and their treatment. By taking part in a research study, you can help to prove the efficacy and new indications of both new and current medications.

Pacific Pulmonary Medical Group physicians are proud to be part of a global medical community committed to finding the cures of tomorrow.

We are currently enrolling for the following Clinical Trials:

The CORE-HH study is developing a new investigational blood test for early cancer detection.
If you are between the ages of 20-79, you may be eligible to participate in a research study to detect a variety of cancer types, even at the earliest stages.
The CORE-HH study is seeking individuals recently diagnosed with cancer, who have not yet received treatment, and individuals not suspected of having cancer to join the study by donating one or more blood samples.


• You will be able to review the study details and provide consent to participate.
• Donate your blood. A 40 ml blood sample (four 10 ml tubes, which is about the same as three
tablespoons) will be taken. Additional samples will be taken if you participate in extended follow-up.
• For a selected group of individuals, two or three additional 40 ml blood draws will be scheduled over the next 12 months based upon your care plan.

There is no cost to you or your insurance company. You will receive $25 for participating in the study and additional compensation for the extra blood draws.

Ask your doctor today about how you can join the CORE-HH study.

The NOBLE trial is a prospective, multicenter study involving up to 50 sites globally. It is anticipated to enroll 9,000 individuals with lung nodules detected through CT imaging either via lung cancer screening or incidentally and will include patients who are benign at initial nodule diagnosis but who subsequently develop lung cancer. Researchers will collect nasal-swab, longitudinal blood and other samples, as well as imaging and clinical information at enrollment and at multiple points throughout the study. Patients will be followed according to current guidelines for three years or until a lung cancer diagnosis.

CliNIcal Utility of ManaGement of Patients witH CT and LDCT Identified Pulmonary Nodules UsinG the Percepta NasAL Swab ClassifiEr (NIGHTINGALE) – Familiarization and Qualification Protocol.

This is a multicenter observational, prospective study.  The goal of if is to evaluate clinical site workflow and ability to integrate the Percepta Nasal Swab test into the assessment of pulmonary nodules, and to demonstrate adequacy of the required processes for participation in a clinical utility study of the Percepta Nasal Swab test.

If you are interested in participating in a clinical trial or have questions, please contact our Clinical Research Coordinator at 951-373-5827